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Skin testing in patients with hypersensitivity reactions to iodinated
contrast media – a European multicenter study
Iodinated contrast media (CM) are highly concentrated
solutions of iodinated benzene derivatives, used to
enhance X-ray procedures (1). Although these products
are regarded as relatively safe, they are known to cause
both immediate ( £ 1 h) and nonimmediate (>1 h)
hypersensitivity reactions in susceptible individuals (2).
Background: Iodinated contrast media cause both immediate and nonimmediate
hypersensitivity reactions. The aim of this prospective study was to determine
the speciﬁcity and sensitivity of skin tests in patients who have experienced such
reactions.
Methods: Skin prick, intradermal and patch tests with a series of contrast
media were conducted in 220 patients with either immediate or nonimmedi-
ate reaction. Positive skin tests were deﬁned according to internationally
accepted guidelines. Seventy-one never-exposed subjects and 11 subjects who
had tolerated contrast medium exposure, served as negative controls.
Results: Skin test speciﬁcity was 96–100%. For tests conducted within the
time period from 2 to 6 months after the reaction, up to 50% of immediate
reactors and up to 47% of nonimmediate reactors were skin test positive. For
immediate reactors, the intradermal tests were the most sensitive, whereas
delayed intradermal tests in combination with patch tests were needed for
optimal sensitivity in nonimmediate reactors. Contrast medium cross-reactivity
was more common in the nonimmediate than in the immediate group. Inter-
estingly, 49% of immediate and 52% of nonimmediate symptoms occurred in
previously unexposed patients. Many of these patients were skin test positive,
indicating that they were already sensitized at the time of ﬁrst contrast medium
exposure.
Conclusions: These data suggest that at least 50% of hypersensitivity reactions to
contrast media are caused by an immunological mechanism. Skin testing appears
to be a useful tool for diagnosis of contrast medium allergy and may play an
important role in selection of a safe product in previous reactors.
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Immediate hypersensitivity reactions to CM are mainly
anaphylactic reactions that can be severe or even fatal
(3), whereas nonimmediate reactions predominantly
manifest themselves as exanthematous skin eruptions
occurring hours to days after CM application [reviewed
in Ref. (4)]. Even the newer generation CM cause
immediate and nonimmediate reactions in about 1–3%
of applications (2). These reactions are a serious
problem considering that more than 75 million CM-
enhanced X-ray procedures are conducted yearly world
wide (5).
CM-induced hypersensitivity reactions have tradition-
ally been classiﬁed as nonallergic reactions (6), and skin
tests have been regarded as inappropriate tools in
patients having experienced such reactions. However,
during the last few years several investigators have
reported positive skin tests in patients with both
immediate and nonimmediate hypersensitivity reactions
after CM exposure, which indicates that immunological
mechanisms may be involved (7–15). The European
Network of Drug Allergy (ENDA; the EAACI interest
group on drug hypersensitivity) therefore designed a
prospective multicenter study to explore the sensitivity
and speciﬁcity of skin tests in patients who reported
typical features of CM hypersensitivity reactions. In
this paper we report the results from the ﬁrst 4 years of
study.
Methods
Patients and negative control subjects
Patients who were referred to the 12 allergy departments of the
ENDA CM task force members because of a reported previous
hypersensitivity reaction after CM exposure were included in the
study. Most cases (95%) were prospectively collected over a 4-
year period from January 2003 to December 2006. Eight patients
in the immediate group and two patients in the nonimmediate
group were tested prior to 2003. The same standardized proce-
dures were used in all patients. Clinical data were recorded using
an adaptation of the ENDA drug allergy questionnaire (16). The
hypersensitivity reaction was classiﬁed as immediate (onset £ 1 h
after CM administration) or nonimmediate (onset >1 h after CM
administration). For immediate reactions the severity scale of
Ring and Messmer (17) was used: grade I: generalized cutaneous
and/or mucocutaneous symptoms; grade II: mild systemic reac-
tions; grade III: life-threatening systemic reactions; grade IV:
cardiac and/or respiratory arrest. In patients with nonimmediate
hypersensitivity reactions, the reaction was graded as mild when
no treatment was required, moderate when the patient responded
readily to appropriate treatment and no hospitalization was
needed, and severe when the reaction required hospitalization or
was life-threatening.
Seventy-one subjects never exposed to any CM and 11 subjects
who had tolerated CM exposure could be recruited on a volun-
tary basis as negative controls. Before testing, informed consent
was obtained from all control subjects for whom the skin
tests were not part of the recommended routine allergological
workup. The study was approved by regional institutional review
boards.
Skin testing
Skin testing was performed with a minimum delay of 1 week and a
median delay of 6 months after the CM-induced hypersensitivity
reaction. Skin prick tests (SPTs) with undiluted CM were followed
by intradermal tests (IDTs) with 10-fold diluted CM and patch tests
(PTs) with undiluted CM. SPTs were performed on the volar
forearm, and were read after 20 min and on days 2 and 3. The SPT
was considered positive if a wheal of ‡ 3 mm in diameter was
observed after 20 min (immediate reading) or if an erythematous
induration occurred at the skin test site on days 2 or 3 (delayed
reading). Intradermal tests were conducted on either the volar
forearm or the back. The test solution (0.03–0.05 ml) was injected
into the skin to produce a bleb of 4–5 mm in diameter. Readings
were conducted after 20 min and on days 1, 2 and 3. The IDT was
regarded as positive if the size of the initial wheal had increased by
at least 3 mm in diameter and was surrounded by erythema after 20
min (immediate) or if an erythematous induration at the skin test
site was present in the delayed readings. Histamine (0.01%) and
saline (0.9%) served as positive and negative controls, respectively.
Patch tests were conducted with CM soaked on a ﬁlter paper in a 12
mm aluminium Finn chamber, ﬁxed with adhesive tape on the back
for 2 days. Readings were conducted 15 min after removal of the
strips and 24 h later in accordance with the recommendations of the
European Society of Contact Dermatitis (18). Patients were
instructed to return to the treating physician in case of positive
reactions at other time points.
Patients were skin tested with the culprit CM (if known) and as
many of the following 13 CM as could be practically handled in the
respective allergy centers: The three ionic monomers sodium ami-
dotrizoate, ioxithalamate and iodamide; the ionic dimer ioxaglate;
the seven nonionic monomers iohexol, iomeprol, iobitridol,
iopamidol, ioversol, iopromide and iopentol; and the two nonionic
dimers iodixanol and iotrolan. All solutions had a strength of 300–
320 mgI/ml.
All the above listed CM were used for skin testing in 31 or more
nonexposed individuals. While iodamide was tested only in 1 CM
exposed control, the other 12 CM were tested in 7 or more of the 11
individuals in this group. SPT, IDT and PT with immediate and late
readings were conducted, as described above.
A history of a typical drug hypersensitivity reaction after
administration of CM was used as a gold standard, and skin test
sensitivity was calculated as the percentage of skin test positive
among these patients. Skin test speciﬁcity was calculated as the
percent of negative controls with positive skin test to any of the
tested CM, indicating possible irritative skin test reactions.
Statistical methods
Two-sided 95% conﬁdence intervals (CI) for frequencies were
based on Kaplan–Meier estimates, using Minitab 12 software. The
Fisher exact test was used for statistical comparison between




Table 1 summarizes the information collected from the
220 investigated patients with well-characterized features
of either immediate (122 patients) or nonimmediate (98
patients) hypersensitivity reactions after CM administra-
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tion. The median age at the time of the diagnostic testing
was 54 years (age range 12–83) for patients in the
immediate group and 58 years (age range 12–80) for
patients in the nonimmediate group.
Signiﬁcantly more patients reported hypersensitivity
reactions after intravenous than after intra-arterial CM
administration (98% vs 2% respectively). Sixty-two
percent of patients in the immediate group and 49% of
patients in the nonimmediate group reported a history of
allergy. Other drug allergies were said to have aﬀected
28% of the patients with immediate reaction and 29% of
those with nonimmediate reaction. None of the patients
in either group claimed to suﬀer from seafood allergy.
Only 53 of 108 patients (49%) in the immediate group
and 48 of 92 (52%) in the nonimmediate group had a
reported history of prior CM exposure. Information
about prior CM exposure was available for 23 of the 27
patients with immediate grade III reactions. Only 12 of
these patients had previously been exposed to a CM. Of
the two patients with grade IV reaction, 1 received a CM
for the ﬁrst time.
For 137 patients, the implicated CM was known.
Reactions to nonionic CM were far more frequent than
reactions to ionic CM (120 vs 15), reﬂecting their current
much greater usage. While there was no signiﬁcant
diﬀerence in frequency of immediate reactions to the
diﬀerent nonionic CM, iodixanol caused late reactions
signiﬁcantly more often than the other nonionic products
(P < 0.05). However, it should be noted that the relative
frequency of use of the diﬀerent nonionic CM in the
diﬀerent centers was unknown.
Clinical characteristics of the reported hypersensitivity reactions
Clinical manifestations. Cutaneous, respiratory, gastro-
intestinal and cardiovascular organ systems were all
frequently involved in the immediate reactions, while skin
reactions were the main manifestations of the nonimme-
diate reactions (Table 2). Immediate skin reactions were
urticaria, angioedema and erythema, whereas nonimme-
diate skin reactions were various types of skin rashes
such as macular and maculopapular exanthema, as well
as urticaria-like rashes and angioedema. Nausea, vomit-
ing, dyspnoea and hypotension were the main noncuta-
neous symptoms aﬀecting the immediate reactors.
Severity. The severity of the immediate reactions was
grade I in 38 patients (31%), grade II in 55 patients
(45%), grade III in 27 (22%) and grade IV in 2 patients
(1.6%). Four patients with grade III reaction were known
to be premedicated with anti-histamines and/or steroids,
but the regimens used were not speciﬁed. Medical
treatment was reported for 78% of patients. The type
of treatment depended on symptoms.
Nonimmediate reactions were mainly mild to moderate
skin eruptions (81%) that were often treated with either
antihistamines (12%), corticosteroids (31%) or a combi-
nation of the two (42%). Hospitalization was reported for
two patients. Occasionally, more severe skin eruptions
were observed. These were bullous exanthema, ﬂexural
exanthema, palpable purpura, purpura/maculopapular
eruption combined with eosinophilia, psoriasis-like exan-
thema, acute generalized exanthematous pustulosis
(AGEP) and exfoliative eruption (each type of eruption
reported once). Of the three patients with nonimmediate
cardiovascular symptoms, only one was known to suﬀer
from cardiovascular disease. She reported bronchospasm
and cardio-respiratory arrest 12 h after a computed






Total number 122 98
Female gender 80 (66) 57 (58)
History of allergy 77 (62) 48 (49)
Asthma bronchiale 19 (16) 9 (9)
Rhinoconjuctivitis 40 (33) 14 (14)
Other drug allergies 34 (28) 28 (29)
Contact allergy 12 (10) 16 (16)
Known prior exposure 53/108 (49) 48/91 (53)







Iobitridol (nonionic monomer) 5 4
Iohexol (nonionic monomer) 6 5
Iomeprol (nonionic monomer) 17 12
Iopamidol (nonionic monomer) 6 3
Iopentol (nonionic monomer) 1 7
Iopromide (nonionic monomer) 12 8
Ioversol (nonionic monomer) 3 2
Iodixanol (nonionic dimer) 4 26
Ioxithalamate (ionic monomer) 5 4
Amidotrizoate (ionic monomer) – 1
Ioxaglate (ionic dimer) 4 –
Others – 5
Unknown 59 24
Table 2. Clinical manifestations of immediate and nonimmediate hypersensitivity
reactions to iodinated contrast media
Symptoms Immediate (%) Nonimmediate (%)
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tomographic thorax examination. The other two patients
reported unspeciﬁed collapse after 3 and 24 h, respec-
tively. Only the patient with unspeciﬁc collapse after 24 h
had a history of previous CM administration.
Repeated reactions. Of the 53 patients in the immediate
group who reported prior CM exposure, 28 (53%) had
experienced a previous reaction. The symptoms of the
reactions were known in 22 cases. The repeated reaction
was of the same grade as the previous reaction in 15 and
more severe in 7. For six of these seven patients the
repeated reaction was of grade III and occurred despite
known premedication in four.
Repeated reactions were less frequent in the nonimme-
diate group. Of the 48 patients with known prior CM
exposure, only 12 (25%) reported a previous reaction
which in 3 occurred despite premedication. All patients
with nonimmediate repeated reactions experienced the
same symptoms on each occasion.
No patients experienced ﬁrst a nonimmediate reaction
and subsequently an immediate reaction or vice versa.
Time to onset of reaction. Time to onset of the reaction
was known for 107 patients in the immediate group and
for 95 patients in the nonimmediate group. Reaction
within 1–5 min after CM injection was recorded in 72
immediate reactors, after 10–15 min in 19, after 20–30
min in 13 and after 45–60 min in 3. For the nonimmediate
reactors, the latency was 1–6 h in 18, 7–12 h in 21, 13–24
h in 21, >1–2 days in 14, >2–3 days in 9 and >3 days in
12. As shown in Fig. 1, there was no diﬀerence in the
delay between CM injection and the onset of symptoms in
patients having previous CM exposure or not. There was
no tendency that the more severe immediate reactions
were reported to occur more rapidly than the less severe
reactions.
Skin test results
Immediate reactors. Positive skin tests were observed in
32 of 122 patients with immediate reaction (26%; 95%
CI: 18–34%). Only 4 of the 122 patients had positive SPT.
Intradermal tests were positive in 30/121 patients (25%)
when read after 20 min and in 3/121 patients (2.5%) when
read after 10–24 h. One patient with a severe anaphylaxis
to an unknown ionic CM 28 years previously, experi-
enced a systemic reaction consisting of urticaria, rhino-
conjuntivitis and glottis edema 5 min after an IDT with a
nonionic CM, whereas all SPTs had been negative.
Positive immediate IDT to at least one of the tested
CM was observed in 3/71 of the unexposed controls, but
in none of the 11 CM-exposed controls. Thus, the
speciﬁcity of the IDT was 96.3% (95% CI: 92–100%).
Each patient was only skin tested on one occasion. The
percentage of patients with positive skin tests varied
according to the time between reaction and testing
(Table 3). While the frequency of positive test results
was 14/28 (50%) in patients tested within 2–6 months, it
was only 17/92 (18%) for patients tested at other time
points (earlier than 2 months or later than 6 months).
This diﬀerence was statistically signiﬁcant (P = 0.0003).
Interestingly, 43% of the patients with positive skin tests
had reacted to a CM on ﬁrst exposure.
For patients tested within the optimal time period 2–6
months after the reaction, there were no more patients
with severe reactions nor patients with a history of allergy
in the skin test positive group than in the skin test
negative group (data not shown).
The CM that had caused the reaction was known for 28
of the skin test positive patients. Twenty-four of them
(86%) tested positive to the implicated CM. Twenty-
seven of the 32 skin test positive patients were tested with
4 or more CM. In each case, at least one product was skin
test negative. More extensive cross-reactivity testing with
8 or more CM was conducted in 11 patients. The results
are shown in Table 4. Six patients were positive to only
one product, two patients were positive to two products,
while more extensive cross-reactivity was observed in the
remaining three patients. Cross-reactivity between ionic
and nonionic CM was reported in 4 of the 11 patients.
Nonimmediate reactors. Delayed skin tests were positive
































Time to onset of reaction 
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Figure 1. Time to onset of immediate (A) and nonimmediate
(B) reactions for patients with (d) or without (s) previous
contrast medium exposure.
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28–47%). Delayed SPTs were only positive in 3 of the 98
reactors. Thirty-one patients (32%) had positive delayed
IDTs that became positive on day 1 in 9 patients, on day
2 in 16 patients and on day 3 in the remaining 6 patients.
Patch tests were conducted in 79 patients and 22 (28%)
tested positive: 3 were positive on day 2 only, 10 required
readings on day 3 to detect all positive reactions and 1
tested positive only on day 3. Nine patients were delayed
IDT positive but PT negative, while seven patients were
delayed IDT negative but PT positive. Two patients with
angioedema 12–14 h after CM exposure were SPT and
IDT positive only at the 20 min reading. None of the 82
negative controls had a positive delayed skin test.
While 47% (29/62) of patients were skin test positive
when tested within the ﬁrst 6 months after reactions, only
22% (8/36) were positive when tested at later time points
(P = 0.02) (Table 3). Interestingly, 33% of patients with
positive delayed skin tests had reacted on their ﬁrst
exposure to a CM.
Patients in the delayed skin test positive group diﬀered
from those in the skin test negative group with regard to
the clinical manifestations of the delayed skin reaction.
For those tested within the ﬁrst 6 months after reaction,
there was a signiﬁcantly higher number of patients with
maculopapular exanthema and a signiﬁcantly lower
number of patients with urticaria-like exanthema in the
skin test positive group (19/29 vs 12/33; P = 0.04 and
1/29 vs 10/33; P = 0.007, respectively).
Thirty-three of the skin test positive patients were skin
tested with the CM that had caused the nonimmediate
hypersensitivity reaction. Twenty-eight (85%) tested
positive to the culprit CM. Thirty-three of the 37 delayed
skin test positive patients were tested with four or more
products. Only 1 patient reacted to all CM used for
testing (four CM in this case). Twenty-ﬁve of the 37
delayed skin test positive patients were tested with at least
8 CM (Table 5). Cross-reactivity was especially pro-
nounced among the CM of very similar chemical struc-
ture such as iodixanol, iohexol, iopentol, iomeprol and
ioversol.
Discussion
Despite the introduction of nonionic, low-osmolar CM,
hypersensitivity reactions still occur in a signiﬁcant
proportion of patients, and life-threatening anaphylactic
reactions are still a major concern both for the radiolo-
gists and the patients involved. It is therefore important
to establish whether skin testing is useful in this setting. In
this ﬁrst European multicenter skin test study, involving
experts in the ﬁeld of CM hypersensitivity (7–13, 19), 220
patients with either previous immediate (n=122) or
nonimmediate (n=98) hypersensitivity reactions were
recruited. It was shown that up to about 50% of patients
in both groups could be diagnosed by standardized skin
tests, if testing was conducted within 2–6 months after the
reaction. This is in accordance with the results reported
by the French CIRTACI group (14). At later time points,
the frequency of positive tests decreased signiﬁcantly,
especially for patients in the immediate group. This could
be due to loss of sensitization over time as reported for
other drug allergies (20) or a decreased reliability of the
patients history.
The speciﬁcities of our delayed IDT and PT were both
100%. Our immediate IDT had a speciﬁcity of 96.3%,
which is slightly lower than the 97.6% reported by
Guillen Toledo and Guido Bayardo (21) in their large
study in 178 439 patients.
For unknown reasons, almost all hypersensitivity reac-
tions occurred after intravenous administration of CM.
The reported time interval between CM exposure and
reaction was within 15 min in the majority of patients with
immediate reactions, which is in accordance with previous
Table 3. Effect of time period between reaction and skin testing on frequency of
positive tests in patients with reported prior immediate and nonimmediate hyper-
sensitivity reaction, respectively
Time from reaction to
skin testing









1 week to 1.5 months 18 3 (17) 19 9 (47)
2 months 8 3 (38) 20 7 (35)
3 months 7 5 (71) 11 9 (82)
4–6 months 13 6 (46) 12 5 (42)
7–12 months 8 2 (25) 10 2 (20)
>1–3 years 14 4 (29) 7 2 (29)
>3 years 52 8 (15) 18 4 (22)
Unknown 1 1 (50) 1 –
Table 4. Results from cross-reactivity testing of patients with previous immediate




1 2 3 4 5 6 7 8 9 10 11
Nonionic
Iodixanol x x x x x x x x x
Iohexol x x x x x x x x x x
Iopentol x x x x x x x
Ioversol x x x x x x x x x x
Iomeprol x x x x x x x x x x x
Iopamidol x x x x x x x x x x x
Iopromide x x x x x x x x x x
Iobitridol x x x x x x x x x x
Iotrolan x x x x x x
Ionic
Ioxaglate x x x x x x x x x x x
Ioxithalamate x x x x x x x x x
Amidotrizoate x x x x x x x x
Iodamide x
*The contrast media used for skin tested are marked x and the contrast media that
caused the hypersensitivity reactions are highlighted with borders (the implicated
contrast medium was unknown for patient 4). The shaded boxes indicate those
contrast media that gave positive skin tests.
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observations (22). Most patients reported that the nonim-
mediate symptoms appeared within 48 h, which is some-
what faster than observed by others (23). Seventy-six
percent of the immediate reactors reported a grade I or II
reaction. The main clinical features of the immediate
reactions were urticaria, angioedema, dyspnoea and hypo-
tension, sometimes accompanied by nausea and vomiting.
There was no tendency for patients with grade III or IV
reactions to have an increased frequency of positive skin
tests compared to those with grade I or II reactions.
The nonimmediate reactions were mainly mild to
moderate exanthematous skin eruptions as have been
reported by other investigators (23). Skin tests were most
often positive in patients with maculopapular eruptions,
and were very seldom positive in patients with nonim-
mediate urticaria-like rashes. The same observation has
been made for other drug allergies (25).
Immediate reactors were only rarely SPT positive.
Intradermal tests with reading after 20 min are the tests of
highest value for this group of patients. At present we
recommend the use of CM (300–320 mgI/ml) diluted
10-fold in sterile saline, since this concentration has been
shown to give a low frequency of false positive reactions
and since the irritant potential of undiluted CM remains
to be explored. In patients with a history of previous
anaphylaxis, SPTs with undiluted CM and reading after
20 min may be conducted before performing IDTs,
although we have shown in this study that such testing
may give a false sense of security. A panel of several
diﬀerent CM should be tested in an attempt to ﬁnd a skin
test negative product, which might be tolerated in future
X-ray examinations.
In nonimmediate reactors, both delayed IDTs and PTs
were frequently positive. Since some patients tested positive
with only one of these tests, we recommend the use of both
tests in parallel to enhance test sensitivity. Patch tests should
be conducted with undiluted CM. We recommend 10-fold
diluted products also when performing delayed IDTs, since
the rate of false positive testswith undilutedCMis currently
unknown. The CM used for testing need to be carefully
chosen because cross-reactivity between diﬀerent products
is rather common in this group of reactors. Ioxaglate,
iopamidol, iopromide and iobitridol showed limited cross-
reactivity with iodixanol, iohexol, iopentol, ioversol and
iomeprol while frequent cross-reactivities were observed
among products of the latter group.
The fact that up to 47–50% of patients had positive skin
tests when tested 2–6 months after the reaction, indicates
that a signiﬁcant fraction of the CM-induced immediate
and nonimmediate hypersensitivity reactions are immuno-
logic reactions, involving CM-reactive IgE antibodies and
CM-reactive T cells, respectively. In nonimmediate reac-
tions the involvement of T cells has been proven by the
generation of CM-speciﬁc T-cell clones (TCC) (26). The
implication of CM-speciﬁc IgE in immediate reactions is
more controversial. It has been argued that the CM
reactions are nonallergic reactions since patients can react
to a CM on ﬁrst exposure and the reaction does not always
recur. However, the positive immediate skin tests reported
by several investigators, the detection of CM-speciﬁc IgE
antibodies in sera from immediate reactors to ionic CM
(27, 28) as well as the recently reported positive basophil
activation test in three immediate reactors with positive
IDT to the implicated nonionic CM (29), all support an
IgE-mediated mechanism.
More than 30% of the skin test positive patients had
been administered a CM for the ﬁrst time. This lack of a
clear sensitization phase is similar to the situation
described in anaphylaxis to muscle relaxants (30), and
indicates that these previously nonexposed patients may
have already been sensitized. The chemical structure(s)
responsible for the sensitization remains unknown. The




1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25
Nonionic
Iodixanol x x x x x x x x x x x x x x x x x x x x x x x x
Iohexol x x x x x x x x x x x x x x x x x x x x x x x x x
Iopentol x x x x x x x x x x x x x x x x x x x x x
Ioversol x x x x x x x x x x x x x x x x x x x x x x x
Iomeprol x x x x x x x x x x x x x x x x x x x x x x x x
Iopamidol x x x x x x x x x x x x x x x x x x x x x x x x x
Iopromide x x x x x x x x x x x x x x x x x x x x x x x
Iobitridol x x x x x x x x x x x x x x x x x x x x x x x x x
Iotrolan x x x x x x x x x x x x x x x
Ionic
Ioxaglate x x x x x x x x x x x x x x x x x x x x x x x x x
Ioxithalamate x x x x x x x x x x x x x x x x
Amidotrizoate x x x x x x x x x x x x x x x x x x x x x
*The contrast media used for skin tested are marked x, and the contrast media that caused the hypersensitivity reactions are highlighted with borders. (The implicated contrast
medium was unknown for patients 6 and 17 or not used for skin testing in patients 11 and 16.) The shaded boxes indicate those contrast media that were skin test positive.
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diﬀerent patterns of CM cross-reactivity shown in this
study, indicate that several chemical entities may be
involved.
Study limitations. Testing of drug hypersensitivity reac-
tions is traditionally hampered by a multitude of test
methods that diﬀer from one center to the next (31). In
this study, skin test procedures and interpretation of test
results were harmonized, a common skin test protocol
was used, and typical cutaneous drug hypersensitivity
reactions were deﬁned by pictures. However, the study
was driven by enthusiasm and not by funding and thus,
some limitations remained:
1. A history of a hypersensitivity reaction to a CM and
lack of any other obvious triggers was used as a gold
standard. Skin test sensitivity was calculated as the
percentage of skin test positive among these patients.
A recruitment bias, e.g. by missing patients with
milder reactions, is possible and without results from
provocation testing, the skin test sensitivity cannot be
determined with certainty. A signiﬁcant underesti-
mate is likely as has been shown for other drug
allergies (32). In patients with negative skin tests, lack
of test sensitivity, wrong classiﬁcation as presumed
CM hypersensitivity or loss of immunological mem-
ory may be considered. The negative predictive value
of skin tests has yet to be determined. Safe
re-administration of a skin test negative CM has so
far only been published for ﬁve patients with previous
life-threatening immediate reactions (15, 33, 34) and
for nine patients with nonimmediate skin eruptions
(8). The next task for the study group is therefore to
validate the skin test results by collecting data from
planned or accidental re-exposure.
2. The number of controls tested depended on possi-
bilities in each center. Ideally, these controls should
have been exposed to a CM within the last 6 months
without clinical signs of hypersensitivity reaction.
However, such controls were diﬃcult to recruit in the
allergy centers. Therefore most of the negative con-
trols were healthy subjects never exposed to CM or
subjects exposed to a CM a long time ago.
3. Not all centers had the capacity to skin test patients
with all the 13 listed CM. Therefore the number of
selected CM varied between diﬀerent centers and
sometimes from one patient to the next. It was stated
in the protocol that skin tests should be done at least
with the culprit CM when known and with a panel of
four CM representing the four diﬀerent classes (ionic
and nonionic monomers and ionic and nonionic
dimers). Most centers complied with this requirement.
4. Since the patients are seldom informed about the
speciﬁc CM used during their X-ray examinations,
the culprit CM could not be identiﬁed in 83 of the 200
cases collected. This means that the responsible
compound may not have been tested, again resulting
in an underestimation of test sensitivity.
5. In the study, a time interval between reaction and
testing of 4–8 weeks was encouraged, but also other
time points were accepted, resulting in a wide range
of time intervals. The conclusion that the optimal
time interval for skin testing may be between 2 and 6
months is based on cross-sectional data only and has
not yet been proven by longitudinal data.
Conclusions
This multicenter study is the largest study to date that
has investigated the usefulness of skin tests in patients
with immediate and nonimmediate hypersensitivity
reactions to CM. The data presented suggest that at
least 50% of the hypersensitivity reactions to CM are
caused by an immunological mechanism. We emphasize
that a hypersensitivity reaction on ﬁrst exposure to a
CM does not rule out an immune mediated reaction, as
we have shown that a considerable fraction of the
patients with such reactions were in fact skin test
positive. Skin testing seems to be a useful tool for
diagnosis of CM allergy and may play an important
role in selection of a safe product in previous reactors.
The speciﬁcity of our skin tests is as high as 96–100%,
but further studies are required to establish their
negative predictive value.
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